Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colistin versus colistin + meropenem for resistant Klebsiella pyelonephritis
IRCT20221108056446N22Phase 2Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Jan 2026
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in pyelonephritis comparing Colistin monotherapy with Colistin + meropenem (2 arms). Primary endpoint: Best antibiotic treatment method. Started Jan 2026; status: completed.
02
Drugs
colistinmeropenem
03
Conditions
pyelonephritis
Beyond the preview
Go deeper on IRCT20221108056446N22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20221108056446N22.